[1]Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern\[J\]. Lancet, 2020, 395(10223): 470-473.
[2]Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin\[J\]. Nature, 2020, 579(7798): 270-273.
[3]Xiao F, Tang M, Zheng X, et al. Evidence for castrointestinal infection of SARSCoV2\[J\]. Gastroenterology, 2020, 158(6): 1831-1833.
[4]Jiang S, Xia S, Ying T, et al. A novel coronavirus (2019nCoV) causing pneumoniaassociated respiratory syndrome\[J\]. Cell Mol Immunol, 2020, 17(5): 554.
[5]Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention\[J\]. JAMA, 2020. doi: 10.1001/jama.2020.2648.
[6]Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARSCoV2 by fulllength human ACE2\[J\]. Science, 2020, 367(6485): 1444-1448.
[7]Lan J, Ge J, Yu J, et al. Structure of the SARSCoV2 spike receptorbinding domain bound to the ACE2 receptor\[J\]. Nature, 2020, 581(7807): 215-220.
[8]Wrapp D, Wang N, Corbett KS, et al. CryoEM structure of the 2019nCoV spike in the prefusion conformation\[J\]. Science, 2020, 367(6483): 1260-1263.
[9]Walls A, Park Y, Tortorici M, et al. Structure, function, and antigenicity of the SARSCoV2 spike glycoprotein\[J\]. Cell, 2020, 181(2): 281-292.
[10]Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARSCoV2\[J\]. Nature, 2020, 581(7807): 221-224.
[11]Braun E, Sauter D. Furinmediated protein processing in infectious diseases and cancer\[J\]. Clin Transl Immunology, 2019, 8(8): e1073.
[12]Zou X, Chen K, Zou J, et al. Singlecell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019nCoV infection\[J\]. Front Med, 2020, 14(2): 185-192.
[13]Bao L, Deng W, Huang B, et al. The pathogenicity of SARSCoV2 in hACE2 transgenic mice\[J\]. Nature, 2020, 583(7818): 830-833.
[14]Liang W, Feng Z, Rao S, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus\[J\]. Gut, 2020, 69(6): 1141-1143.
[15]Song Y, Liu P, Shi X, et al. SARSCoV2 induced diarrhoea as onset symptom in patient with COVID19\[J\]. Gut, 2020, 69(6): 1143-1144.
[16]Chai P, Yu J, Ge S, et al. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID19) receptor ACE2 in malignancies: a pancancer analysis\[J\]. J Hematol Oncol, 2020, 13(1): 43.
[17]Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019nCoV/SARSCoV2) receptor ACE2 in different populations\[J\]. Cell Discov, 2020, 6(1): 11.
[18]Fu Y, Cheng Y, Wu Y. Understanding SARSCoV2mediated inflammatory responses: from mechanisms to potential therapeutic tools\[J\]. Virol Sin, 2020, 35(3): 266-271.
[19]Monteil V, Kwon H, Prado P, et al. Inhibition of SARSCoV2 infections in engineered human tissues using clinicalgrade soluble human ACE2\[J\]. Cell, 2020, 181(4): 905-913.
[20]Chen L, Zhong L. Lung adenocarcinoma patients own higher risk of SARSCoV2 infection\[J\]. Preprints, 2020, 202002.0386.v1
[21]Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID19\[J\]. Lancet, 2020, 395(10234): 1417-1418.
[22]Ziegler C, Allon S, Nyquist S, et al. SARSCoV2 receptor ACE2 is an interferonstimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues\[J\]. Cell, 2020, 181(5): 1016-1035.
[23]Sungnak W, Huang N, Bécavin C, et al. SARSCoV2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes\[J\]. Nat Med, 2020, 26(5): 681-687.
[24]Li M, Li L, Zhang Y, et al. An investigation of the expression of 2019 novel coronavirus cell receptor gene ACE2 in a wide variety of human tissues\[J\]. Research Square, 2020. doi: 10.21203/rs.2.24751/v2.
[25]Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis\[J\]. J Pathol, 2004, 203(2): 631-637.
[26]Smith J, Sausville E, Girish V, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARSCoV2 receptor ACE2 in the respiratory tract\[J\]. Dev Cell, 2020, 53(5): 514-529.
[27]Song H, Seddighzadeh B, Cooperberg M, et al. Expression of ACE2, the SARSCoV2 receptor, and TMPRSS2 in prostate epithelial cells\[J\]. Eur Urol, 2020, 78(2): 296-298.
[28]Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study\[J\]. Lancet, 2020, 395(10223): 507-513.
[29]Hoffmann M, KleineWeber H, Schroeder S, et al. SARSCoV2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor\[J\]. Cell, 2020, 181(2): 271-280.
[30]Li J, Zhang Y, Wang F, et al. Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID19) and severe condition\[J\]. medRxiv, 2020. doi: 10.1101/2020.02.27.20027524.
[31]Srensen M, Srensen B, GonzalezDosal R, et al. Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals\[J\]. Ann N Y Acad Sci, 2006, 1067: 500-505.
[32]Park J, Jung S, Kim A, et al. MERS transmission and risk factors: a systematic review\[J\]. BMC Public Health, 2018, 18(1): 574.
[33]Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China\[J\]. NEJM, 2020, 382(18): 1708-1720.
[34]Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread\[J\]. J Virol, 2005, 2(1): 69.
[35]Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensinconverting enzyme inhibitors and statins on viral pneumonia\[J\]. Proc (Bayl Univ Med Cent), 2018, 31(4): 419-423.
[36]Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody\[J\]. Emerg Microbes Infect, 2020, 9(1): 382-385.
[37]Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARSCoV2 infection\[J\]. Nature, 2020, 584: 115-119.
[38]Chen X, Li R, Pan Z, et al. Human monoclonal antibodies block the binding of SARSCoV2 spike protein to angiotensin converting enzyme 2 receptor\[J\]. Cell Mol Immunol, 2020, 17(6): 647-649.
[39]Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID19\[J\]. Nat Rev Immunol, 2020, 20(6): 339-341.
[40]Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID19 patients\[J\]. Proc Natl Acad Sci U S A, 2020, 117(17):9490-9496.
[41]Amanat F, Krammer F. SARSCoV2 vaccines: status report\[J\]. Immunity, 2020, 52(4): 583-589. |